Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers

The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective in mice. The investigators intend to screen mutation carriers and controls for the presence of Prion autoantibodies.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prion Diseases Central Nervous System Diseases Central Nervous System Infections Infections Nervous System Diseases Neurodegenerative Diseases

Age range

1 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University Graz, Graz, Austria

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Relatives of patients of genetic Prion diseases
Obtained informed consent

Exclusion criteria

No informed consent

Treatment and study plan

Blood Draw

Other

Primary outcomes

Anti-Prion protein autoantibody levels

Time frame: Baseline, up to 90 years

Sponsors and collaborators

Lead sponsor

University of Zurich

Other

Registry information

Acronym: PRNP

Important dates

Study start: 2015
Primary completion: 2018
Study completion: 2019
First posted: Jul 20, 2016
Registry last updated: May 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting